- Xu, Jun;
- Ma, Hsiao-Yen;
- Liu, Xiao;
- Rosenthal, Sara;
- Baglieri, Jacopo;
- McCubbin, Ryan;
- Sun, Mengxi;
- Koyama, Yukinori;
- Geoffroy, Cedric G;
- Saijo, Kaoru;
- Shang, Linshan;
- Nishio, Takahiro;
- Maricic, Igor;
- Kreifeldt, Max;
- Kusumanchi, Praveen;
- Roberts, Amanda;
- Zheng, Binhai;
- Kumar, Vipin;
- Zengler, Karsten;
- Pizzo, Donald P;
- Hosseini, Mojgan;
- Contet, Candice;
- Glass, Christopher K;
- Liangpunsakul, Suthat;
- Tsukamoto, Hidekazu;
- Gao, Bin;
- Karin, Michael;
- Brenner, David A;
- Koob, George F;
- Kisseleva, Tatiana
Chronic alcohol abuse has a detrimental effect on the brain and liver. There is no effective treatment for these patients, and the mechanism underlying alcohol addiction and consequent alcohol-induced damage of the liver/brain axis remains unresolved. We compared experimental models of alcoholic liver disease (ALD) and alcohol dependence in mice and demonstrated that genetic ablation of IL-17 receptor A (IL-17ra-/-) or pharmacological blockade of IL-17 signaling effectively suppressed the increased voluntary alcohol drinking in alcohol-dependent mice and blocked alcohol-induced hepatocellular and neurological damage. The level of circulating IL-17A positively correlated with the alcohol use in excessive drinkers and was further increased in patients with ALD as compared with healthy individuals. Our data suggest that IL-17A is a common mediator of excessive alcohol consumption and alcohol-induced liver/brain injury, and targeting IL-17A may provide a novel strategy for treatment of alcohol-induced pathology.